478 related articles for article (PubMed ID: 30679326)
41. Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome.
Luque Paz D; Chauveau A; Boyer F; Buors C; Samaison L; Cottin L; Seegers V; Férec C; Le Maréchal C; Gueguen P; Lippert E; Ianotto JC; Ugo V
Genes Chromosomes Cancer; 2017 May; 56(5):354-362. PubMed ID: 27997717
[TBL] [Abstract][Full Text] [Related]
42. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.
Tashi T; Swierczek S; Kim SJ; Salama ME; Song J; Heikal N; King KY; Hickman K; Litton S; Prchal JT
Leukemia; 2018 Aug; 32(8):1830-1833. PubMed ID: 29556018
[No Abstract] [Full Text] [Related]
43. Relevance of early diagnosis in polycythemia vera and essential thrombocythemia: A single center's experience.
Lakhwani S; Pardina-Echevarría M; Arcas-Vega R; Díaz-Sánchez OR; Hernández-García MT; Raya JM
Rev Clin Esp (Barc); 2022 Mar; 222(3):169-173. PubMed ID: 34657827
[TBL] [Abstract][Full Text] [Related]
44. The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.
Barbui T; Thiele J; Carobbio A; Vannucchi AM; Tefferi A
Leukemia; 2015 Apr; 29(4):992-3. PubMed ID: 25425199
[No Abstract] [Full Text] [Related]
45. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
[TBL] [Abstract][Full Text] [Related]
46. JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes.
Sureau L; Buors C; Ianotto JC; Boyer F; Tanguy-Schmidt A; Roy L; Cayssials E; Cailly L; Chomel JC; Chauveau A; Orvain C; Mansier O; Ranta D; Robles M; Gyan E; Hérault O; Nimubona S; Marchand T; Lippert E; Riou J; Ugo V; Luque Paz D
Blood Cancer J; 2022 Apr; 12(4):56. PubMed ID: 35395836
[No Abstract] [Full Text] [Related]
47. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
48. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.
Bellosillo B; Martínez-Avilés L; Gimeno E; Florensa L; Longarón R; Navarro G; Salar A; Espinet B; Solé F; Serrano S; Besses C
Leukemia; 2007 Jun; 21(6):1331-2. PubMed ID: 17361221
[No Abstract] [Full Text] [Related]
49. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
50. MicroRNA expression and JAK2 allele burden in bone marrow trephine biopsies of polycythemia vera, essential thrombocythemia and early primary myelofibrosis.
Gebauer N; Bernard V; Gebauer W; Feller AC; Merz H
Acta Haematol; 2013; 129(4):251-6. PubMed ID: 23343777
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.
Pardanani A; Tefferi A; Guglielmelli P; Bogani C; Bartalucci N; Rodríguez J; Extremera S; Pérez I; Alfaro V; Vannucchi AM
Blood Cancer J; 2015 Mar; 5(3):e286. PubMed ID: 25768401
[TBL] [Abstract][Full Text] [Related]
52. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
Guglielmelli P; Barosi G; Pieri L; Antonioli E; Bosi A; Vannucchi AM
Haematologica; 2009 Jan; 94(1):144-6. PubMed ID: 19042918
[No Abstract] [Full Text] [Related]
53. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
54. [CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?].
Apel A; Cohen O; Koren-Michowitz M
Harefuah; 2019 Nov; 158(11):737-741. PubMed ID: 31721518
[TBL] [Abstract][Full Text] [Related]
55. Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia.
Godfrey AL; Chen E; Pagano F; Silber Y; Campbell PJ; Green AR
Haematologica; 2013 May; 98(5):718-21. PubMed ID: 23633544
[TBL] [Abstract][Full Text] [Related]
56. Current management strategies for polycythemia vera and essential thrombocythemia.
Guglielmelli P; Vannucchi AM
Blood Rev; 2020 Jul; 42():100714. PubMed ID: 32546373
[TBL] [Abstract][Full Text] [Related]
57. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.
Barbui T; Thiele J; Carobbio A; Guglielmelli P; Rambaldi A; Vannucchi AM; Tefferi A
Am J Hematol; 2014 Jun; 89(6):588-90. PubMed ID: 24535932
[TBL] [Abstract][Full Text] [Related]
58. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
Choi HS; Hong J; Hwang SM; Lee JH; Ma Y; Kim SA; Lee JY; Lee JO; Bang SM
Ann Hematol; 2021 Oct; 100(10):2567-2574. PubMed ID: 34331110
[TBL] [Abstract][Full Text] [Related]
60. Increased Lipocalin 2 level may have important role in thrombotic events in patients with polycythemia vera and essential thrombocythemia.
Rajnics P; Kellner Á; Karádi É; Moizs M; Bödör C; Király PA; Marosvári D; Andrikovics H; Egyed M
Leuk Res; 2016 Sep; 48():101-6. PubMed ID: 27161323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
